Fluidigm Announces Virtual Mass Cytometry Webinar Investor Event on May 24, 2021, at 1:00 p.m. Eastern Time
May 10 2021 - 1:30PM
Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology
tools provider with a vision to improve life through comprehensive
health insight, today announced that it will host a virtual
investor event that will showcase competitive advantages of CyTOF®
technology, preview a new product that will enhance the
capabilities of a Fluidigm mass cytometry platform, and provide
updates on the company’s innovation pipeline and key customer
relationships.
Fluidigm will host this webinar focused on its mass cytometry
business on Monday, May 24, at 1:00 p.m.
ET (10:00 a.m. PT). The session will include presentations by
Fluidigm management, business leads, and customers, as well as a
Q&A segment during a live conference call and webcast.
The goal of the event is to continue to educate current and
prospective investors about Fluidigm’s strategy, its product and
growth pathway, and the company’s role in providing innovative
solutions for current and emerging needs within life science.
As part of enhanced investor outreach, Fluidigm plans to hold
future webinar-based events to provide focused and efficient
engagement on topics of investor interest.
The live webcast can be accessed via the investor relations
section of the Fluidigm® website at Events &
Presentations. Participants can also listen by phone by dialing
(877) 556-5248 in the U.S. or (720) 545-0029 outside the U.S. The
Conference ID for the live call is 3845948. It is recommended to
dial in 15 to 20 minutes prior to the scheduled start time. For
those unable to participate in the live event, the webcast will be
archived on the Fluidigm Investor Relations page at
investors.fluidigm.com.
About Fluidigm Fluidigm (Nasdaq:FLDM)
focuses on the most pressing needs in translational and clinical
research, including cancer, immunology, and immunotherapy. Using
proprietary CyTOF® and microfluidics technologies, we develop,
manufacture, and market multi-omic solutions to drive meaningful
insights in health and disease, identify biomarkers to inform
decisions, and accelerate the development of more effective
therapies. Our customers are leading academic, government,
pharmaceutical, biotechnology, plant and animal research, and
clinical laboratories worldwide. Together with them, we strive to
increase the quality of life for all. For more information,
visit fluidigm.com.Fluidigm, the Fluidigm logo,
Advanta, and CyTOF are trademarks and/or registered trademarks
of Fluidigm Corporation in the United
States and/or other countries. All other trademarks are
the sole property of their respective owners. The Advanta Dx
SARS-CoV-2 RT-PCR Assay is for In Vitro Diagnostic Use. It is for
Use under Emergency Use Authorization Only. Rx Only. Other
Fluidigm products are provided for Research Use Only. Not for
use in diagnostic procedures.
Available InformationWe use our website
(fluidigm.com), investor site (investors.fluidigm.com), corporate
Twitter account (@fluidigm), Facebook page (facebook.com/Fluidigm),
and LinkedIn page (linkedin.com/company/fluidigm-corporation) as
channels of distribution of information about our products, our
planned financial and other announcements, our attendance at
upcoming investor and industry conferences, and other matters. Such
information may be deemed material information, and we may use
these channels to comply with our disclosure obligations under
Regulation FD. Therefore, investors should monitor our website and
our social media accounts in addition to following our press
releases, SEC filings, public conference calls, and
webcasts.
Contacts:Investors:Peter DeNardo415 389 6400ir@fluidigm.com
Media:Mark SpearmanSenior Director, Corporate Communications650
243 6621mark.spearman@fluidigm.com
Fluidigm (NASDAQ:FLDM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Fluidigm (NASDAQ:FLDM)
Historical Stock Chart
From Sep 2023 to Sep 2024